A case of multiple sclerosis improvement following removal of heavy metal intoxication

BioMetals

Volumn 25, Issue 3, 2012, Pages 569-576

  Fulgenzi, Alessandro ^a   Zanella, Sante Guido ^a   Mariani, Mario Mauro ^a   Vietti, Daniele ^a   Ferrero, Maria Elena ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Chelation therapy; EDTA; Multiple sclerosis; Toxic heavy metals

Indexed keywords

ALUMINUM; ANTIOXIDANT; ASCORBIC ACID; AZATHIOPRINE; DEUTROSULFAZYME; EDETATE CALCIUM DISODIUM; GADOLINIUM; GLUTATHIONE; LEAD; MERCURY; METHYLPREDNISOLONE; MITOXANTRONE; STEROID; THIOCTIC ACID; UNCLASSIFIED DRUG; VITAMIN B GROUP;

ADULT; ARTICLE; CASE REPORT; CHELATION THERAPY; DEGENERATIVE DISEASE; DISEASE COURSE; DRUG DETOXIFICATION; DRUG PULSE THERAPY; DRUG WITHDRAWAL; HEAVY METAL POISONING; HUMAN; IN VIVO STUDY; MALE; MEDICAL HISTORY; MULTIPLE CYCLE TREATMENT; MULTIPLE SCLEROSIS; OPTIC NEURITIS; OUTCOME ASSESSMENT; REMISSION; STEROID THERAPY; URINE LEVEL;

ADULT; CHELATING AGENTS; EDETIC ACID; HUMANS; MALE; METALS, HEAVY; MULTIPLE SCLEROSIS; YOUNG ADULT;

EID: 84864917369     PISSN: 09660844     EISSN: 15728773     Source Type: Journal    
DOI: 10.1007/s10534-012-9537-7     Document Type: Article

References (40)

1. Bakshi R, Hutton GJ, Miller JR, Radue EW (2004) The use of magnetic resonance imaging in the diagnosis and longterm management of multiple sclerosis. Neurology 63(11 Suppl 5):S3-S11
2. Barkhof F, Filippi M, Miller DH, Scheltens P, Campi A, Polman CH, Comi G, Ader HJ, Losseff N, Valk J (1997) Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 120(Pt 11):2059-2069
3. Bolli MH, Lescop C, Nayler O (2011) Synthetic sphingosine 1-phosphate receptor modulators-opportunities and potential pitfalls. Curr Top Med Chem 11(6):726-757
4. Bolt HM, Thier R (2006) Relevance of the deletion polymorphisms of the glutathione S-transferases GSTT1 and GSTM1 in pharmacology and toxicology. Curr Drug Metab 7(6):613-628
5. Ceccatelli S, Dare E, Moors M (2010) Methylmercury-induced neurotoxicity and apoptosis. Chem Biol Interact 188(2): 301-308. doi:10.1016/j.cbi.2010.04.007
6. Chen Y, Bord E, Tompkins T, Miller J, Tan CS, Kinkel RP, Stein MC, Viscidi RP, Ngo LH, Koralnik IJ (2009) Asymptomatic reactivation of JC virus in patients treated with natalizumab. N Engl J Med 361(11):1067-1074. doi: 10.1056/NEJMoa0904267
7. Clarkson TW (1987) Metal toxicity in the central nervous system. Environ Health Perspect 75:59-64
8. Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L (2010) Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 362(5):402-415. doi:10.1056/NEJMoa0907839
9. Corsello S, Fulgenzi A, Vietti D, Ferrero ME (2009) The usefulness of chelation therapy for the remission of symptoms caused by previous treatment with mercury-containing pharmaceuticals: a case report. Cases J 2:199. doi: 10.1186/1757-1626-2-199
10. Davidovics Z, DiCicco-Bloom E (2005) Moderate lead exposureelicits neurotrophic effects in cerebral cortical precursor cells in culture. J Neurosci Res 80(6):817-825. doi: 10.1002/jnr.20539
11. Exley C, Mamutse G, Korchazhkina O, Pye E, Strekopytov S, Polwart A, Hawkins C (2006) Elevated urinary excretion of aluminium and iron in multiple sclerosis. Mult Scler 12(5):533-540
12. Feng X, Xia Q, Yuan L, Yang X, Wang K (2010) Impaired mitochondrial function and oxidative stress in rat cortical neurons: implications for gadolinium-induced neurotoxicity. Neurotoxicology 31(4):391-398. doi:10.1016/j.neuro. 2010.04.003
13. Goncalves MS, Moura Neto JP, Souza CL, Melo P, Reis MG (2010) Evaluating glutathione S-transferase (GST) null genotypes (GSTT1 and GSTM1) as a potential biomarker of predisposition for developing leukopenia. Int J Lab Hematol 32(1 Pt 1):e49-e56. doi:10.1111/j.1751-553X. 2009.01169.x
14. Graves J, Balcer LJ (2010) Eye disorders in patients with multiple sclerosis: natural history and management. Clin Ophthalmol 4:1409-1422. doi:10.2147/OPTH.S6383
15. Gundacker C, Komarnicki G, Jagiello P, Gencikova A, Dahmen N, Wittmann KJ, Gencik M (2007) Glutathione-S-transferase polymorphism, metallothionein expression, and mercury levels among students in Austria. Sci Total Environ 385(1-3):37-47. doi:10.1016/j.scitotenv.2007. 07.033
16. Ibrahim SM, Gold R (2005) Genomics, proteomics, metabolomics: what is in a word for multiple sclerosis? Curr Opin Neurol 18(3):231-235
17. Kumar V, Gill KD (2009) Aluminium neurotoxicity: neurobehavioural and oxidative aspects. Arch Toxicol 83(11):965-978. doi:10.1007/s00204-009-0455-6
18. Lin JL, Lin-Tan DT, Hsu KH, Yu CC (2003) Environmental lead exposure and progression of chronic renal diseases in patients without diabetes. N Engl J Med 348(4):277-286. doi:10.1056/NEJMoa021672
19. Linda H, von Heijne A, Major EO, Ryschkewitsch C, Berg J, Olsson T, Martin C (2009) Progressive multifocal leukoencephalopathy after natalizumab monotherapy. N Engl J Med 361(11):1081-1087. doi:10.1056/NEJM a0810316
20. Major EO (2009) Reemergence of PML in natalizumab-treated patients-new cases, same concerns. N Engl J Med 361(11):1041-1043. doi:10.1056/NEJMp0906248
21. Milo R, Panitch H (2011) Combination therapy in multiple sclerosis. J Neuroimmunol 231(1-2):23-31. doi:10.1016/ j.jneuroim.2010.10.021
22. Monroe RK, Halvorsen SW (2009) Environmental toxicants inhibit neuronal Jak tyrosine kinase by mitochondrial disruption. Neurotoxicology 30(4):589-598. doi:10.1016/ j.neuro.2009.03.007
23. Ott SM, Andress DL, Nebeker HG, Milliner DS, Maloney NA, Coburn JW, Sherrard DJ (1986) Changes in bone histology after treatment with desferrioxamine. Kidney Int Suppl 18:S108-S113
24. Pentyala S, Ruggeri J, Veerraju A, Yu Z, Bhatia A, Desaiah D, Vig P (2010) Microsomal Ca2? flux modulation as an indicator of heavy metal toxicity. Indian J Exp Biol 48(7):737-743
25. Plosker GL (2011) Interferon-beta-1b: a review of its use in multiple sclerosis. CNS Drugs 25(1):67-88. doi:10.2165/ 11206430-000000000-00000
26. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, Lublin FD, Metz LM, McFarland HF, O'Connor PW, Sandberg-Wollheim M, Thompson AJ, Weinshenker BG, Wolinsky JS (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the ''McDonald Criteria''. Ann Neurol 58(6):840-846. doi:10.1002/ana.20703
27. Rai A, Maurya SK, Khare P, Srivastava A, Bandyopadhyay S (2010) Characterization of developmental neurotoxicity of As, Cd, and Pb mixture: synergistic action of metal mixture in glial and neuronal functions. Toxicol Sci 118(2):586-601. doi:10.1093/toxsci/kfq266
28. Reiber H, Teut M, Pohl D, Rostasy KM, Hanefeld F (2009) Paediatric and adult multiple sclerosis: age-related differences and time course of the neuroimmunological response in cerebrospinal fluid. Mult Scler 15(12):1466-1480. doi: 10.1177/1352458509348418
29. Rojo LE, Fernandez JA, Maccioni AA, Jimenez JM, Maccioni RB (2008) Neuroinflammation: implications for the pathogenesis and molecular diagnosis of Alzheimer's disease. Arch Med Res 39(1):1-16. doi:10.1016/j.arcmed.2007.10.001
30. Rosin A (2009) The long-term consequences of exposure to lead. Isr Med Assoc J 11(11):689-694
31. Roussel AM, Hininger-Favier I, Waters RS, Osman M, Fernholz K, Anderson RA (2009) EDTA chelation therapy, without added vitamin C, decreases oxidative DNA damage and lipid peroxidation. Altern Med Rev 14(1):56-61
32. Siblerud RL, Kienholz E (1994) Evidence that mercury from silver dental fillings may be an etiological factor in multiple sclerosis. Sci Total Environ 142(3):191-205
33. Sicotte NL (2011) Neuroimaging in multiple sclerosis: neurotherapeutic implications. Neurotherapeutics 8(1):54-62. doi:10.1007/s13311-010-0008-y
34. Skov A, Skov T, Frederiksen J (2010) Oligoclonal bands predict multiple sclerosis after optic neuritis: a literature survey. Mult Scler 17(4):404-410. doi: 10.1177/1352458510 391340
35. Taber KH, Hurley RA (2008) Mercury exposure: effects across the lifespan. J Neuropsychiatry Clin Neurosci 20(4):4-389. doi:10.1176/appi.neuropsych.20.4. iv
36. Wundes A, Kraft GH, Bowen JD, Gooley TA, Nash RA (2010) Mitoxantrone for worsening multiple sclerosis: tolerability, toxicity, adherence and efficacy in the clinical setting. Clin Neurol Neurosurg 112(10):876-882. doi:10.1016/ j.clineuro.2010.07.018
37. Xia Q, Feng X, Huang H, Du L, Yang X, Wang K (2011) Gadolinium-induced oxidative stress triggers endoplasmic reticulum stress in rat cortical neurons. J Neurochem 117(1):38-47. doi:10.1111/j.1471-4159.2010.07162.x
38. Yang Y, Parsons KK, Chi L, Malakauskas SM, Le TH (2009) Glutathione S-transferase-micro1 regulates vascular smooth muscle cell proliferation, migration, and oxidative stress. Hypertension 54(6):1360-1368. doi:10.1161/HYP ERTENSIONAHA.109.139428
39. Zahran S, Mielke HW, Weiler S, Berry KJ, Gonzales C (2009) Children's blood lead and standardized test performance response as indicators of neurotoxicity in metropolitan New Orleans elementary schools. Neurotoxicology 30(6): 888-897. doi:10.1016/j.neuro.2009.07.017
40. Zhang QL, Niu Q, Niu PY, Shi YT, Liu CY, Di Gioacchino M, Zhang L, Zhang C, Braga M (2010) Bax gene silencing: a potential intervention in aluminum-induced neural cell death. J Biol Regul Homeost Agents 24(1):7-17